BetaFor now, only select medications are available to compare. This data is sourced from the medication label and is not exhaustive.
efficacy
ACR20 Response at Week 12
cDMARD-IR: 66%; TNFi-IR: 49%
cDMARD-IR: 55%; TNFi-IR: 41%
ACR50 Response at Week 12
cDMARD-IR: 34%; TNFi-IR: 20%
cDMARD-IR: 29%; TNFi-IR: 26%
ACR20 Response at Week 24
cDMARD-IR: 61%; TNFi-IR: 45%
cDMARD-IR: 50%; TNFi-IR: 51%
ACR50 Response at Week 24
cDMARD-IR: 41%; TNFi-IR: 23%
cDMARD-IR: 32%; TNFi-IR: 37%
Review efficacy data to choose the clinically appropriate treatment for your patient
safety
Black Box Warning
Yes
Yes
Contraindications
None
None
Most Common Adverse Reactions
In RA (incidence ≥1%): upper respiratory tract infections, nausea, herpes simplex, herpes zoster
In RA within first 3 months of placebo-controlled trials (≥2% with XELJANZ ± DMARDs): upper respiratory tract infection, nasopharyngitis, diarrhea, headache
indications
Adult Rheumatoid Arthritis (moderately to severely active RA with inadequate response to one or more TNF blockers)
Yes
Yes
COVID-19 (hospitalized, requiring oxygen)
Yes
No
Alopecia Areata
Yes
No
Psoriatic Arthritis
No
Yes
Ulcerative Colitis
No
Yes
Ankylosing Spondylitis
No
Yes
Juvenile Idiopathic Arthritis
No
Yes (patients 2+ years)
Coverage
Add insurance carrier above to get more details about the coverage for each medication
dosing
Standard Dosing
2 mg once daily orally, with or without food
5 mg twice daily or XELJANZ XR 11 mg once daily
Mild Renal Impairment Dosing
2 mg once daily
No dose adjustment needed
Moderate Renal Impairment Dosing
1 mg once daily
5 mg once daily
Severe Renal Impairment Dosing
Not recommended
5 mg once daily
Moderate Hepatic Impairment Dosing
No dose adjustment needed
5 mg once daily
pharmacology
Mechanism of Action
JAK1/2 inhibitor with some TYK2 activity
JAK inhibitor with preferential inhibition of JAK1/JAK3 and JAK1/JAK2 combinations
Half-life
~12-16 hours in RA and alopecia areata patients
About 3 hours (immediate-release), 6-8 hours (extended-release)
Time to Peak
1 hour
0.5-1 hours (immediate-release), 4 hours (extended-release)
Bioavailability
~80%
74%
Find savings
No data available
No data available
Alternative Drug Suggestions